In December 2026, Chinese scientist He Jiankui announced the birth of the first genetically modified babies, Lulu and Nana, triggering a global shockwave. This event, dubbed the "He Case" by the scientific community, thrust into the spotlight a debate that had been simmering since the invention of CRISPR-Cas9: how far are we willing to go to "improve" humans? Today, as technology advances by leaps and bounds, the question of germline editing—which modifies reproductive cells and is passed on to offspring—is no longer a science fiction hypothesis. It has become one of the most burning ethical dilemmas of our time.
This article explores the tensions between the therapeutic promises and ethical risks of germline editing, drawing on analyses from institutions such as Harvard, the Hastings Center, and the Innovative Genomics Institute. We will see why the boundary between treatment and enhancement is so contested, what pitfalls to avoid in governing these technologies, and how decisions made today will shape the humanity of tomorrow.
The Therapeutic Promise: Healing at the Root
Germline editing holds immense hope in the medical field. By modifying genes in germ cells (eggs, sperm, or early embryos), it would be possible to permanently eliminate serious hereditary diseases such as cystic fibrosis, Huntington's disease, or certain forms of genetic cancer. Unlike somatic gene therapies, which only affect the treated individual, germline editing would remove the disease from the germline, thus protecting all future generations.
Harvard researchers, in a 2026 roundtable, emphasized the importance of not reacting hastily to such advances. As Professor Cohen, a specialist in the legal consequences of germline editing, recalled: "I think we should slow down our reaction to this case." This caution is essential because, while the therapeutic potential is real, the risks of adverse effects—off-target mutations, mosaicism, unforeseen developmental consequences—are still poorly understood.
> "Germline editing is not just about correcting a defect; it rewrites the genetic code of the species. Each modification is irreversible and propagates infinitely."
The Red Line: Treatment vs. Enhancement
The ethical debate crystallizes around a fundamental distinction: the boundary between therapeutic and enhancement. While correcting pathogenic mutations seems largely acceptable, the idea of using germline editing to enhance "normal" traits—such as intelligence, height, or physical strength—raises powerful objections.
A 2026 Hastings Center report questions this dichotomy: "We do not claim to know whether enhancement constitutes a reasonable ethical boundary for human genome editing." Indeed, the distinction between disease and normality is culturally variable. Where should the line be drawn? Is deafness a disease to correct or a difference to respect? Could parents legitimately want a taller or more athletic child to give them an advantage in life?
The Innovative Genomics Institute (IGI) warns against a dystopian scenario where only the wealthy have access to these technologies, widening a genetic gap between social classes. This prospect of "market eugenics" is one of the strongest arguments against allowing germline editing for enhancement purposes.
Concrete Risks: What Can Go Wrong
Beyond philosophical considerations, germline editing presents very real technical and societal risks. Here are the main pitfalls to watch for:
- Off-target effects: CRISPR-Cas9 can cut DNA at unintended sites, causing potentially cancerous mutations. An erroneous germline modification would be passed on to all descendants.
- Mosaicism: Editing may not affect all cells of the embryo, creating an individual with genetically different cells, complicating diagnosis and monitoring.
- Consent of future generations: Those who inherit the modifications have no say. Is it ethical to decide for them?
- Slippery slope to enhancement: Once the technology is mastered, social and commercial pressure could push toward non-therapeutic uses, as shown by the history of assisted reproductive technology.
A 2026 article in the journal Bioethics notes that current regulatory frameworks are often inadequate: some countries completely ban germline editing, others allow it under conditions, creating "genetic tourism" where parents seek the most permissive jurisdictions.
> "Arguments against human enhancement that rely on dignity or human nature are often difficult to justify universally." (Bostrom & Roache, 2026, cited in Springer)
Governance: Toward an International Consensus?
The scientific community agrees on the need for robust governance, but deep divergences remain. A 2026 report in the AMA Journal of Ethics explores the concept of "prevention" as a framework for germline editing: is it about preventing a disease, suffering, or a certain form of life? Each interpretation leads to different policies.
Warning signs are numerous:
- Lack of transparency: The He Jiankui case showed that researchers can bypass ethics in secret labs.
- Parental pressure: The hope of having a "perfect" child can lead to unreasonable demands.
- Lack of international regulation: Treaties like the Oviedo Convention are too vague or non-binding.
What not to do:
- Do not act in haste: As Cohen reminds us, each spectacular announcement should not precipitate irreversible decisions.
- Do not demonize the technology: Therapeutic germline editing could save lives. A total ban would deprive families of hope.
- Do not ignore the voices of those affected: Patients, disease communities, and citizens must be included in the debate.
Future Perspectives: Germline Editing and Beyond
Germline editing is not limited to Earth. A 2026 Springer article explores its potential role in long-duration space missions: modifying astronauts to withstand radiation or microgravity. This raises even more dizzying questions: how far are we willing to transform humans to explore the universe?
In the meantime, the debate remains open. Institutions like the Hastings Center call for not abandoning ethical concerns in the name of progress. Germline editing is not just a technical issue; it is a mirror held up to our humanity: what do we want to become?
For Further Reading
- Harvard Gazette - Perspectives on gene editing - Harvard researchers share views on future, ethics of gene editing.
- IntechOpen - Editing the Future: Ethical Challenges of Therapeutic Use, Germline Modification and Human Enhancement - Analysis of ethical challenges of germline editing.
- The Hastings Center - What Happened to Concerns About Human Enhancement? - Reflection on the boundary between treatment and enhancement.
- NCBI - Ethical Challenges of Germline Genetic Enhancement - Examination of ethical issues in germline genetic enhancement.
- Genome.gov - Ethical Concerns of Genome Editing - Overview of ethical concerns.
- Innovative Genomics Institute - CRISPR & Ethics - Resource on ethical implications of CRISPR.
- Springer - The Ethical Status of Germline Gene Editing in Future Space Missions - Application of germline editing to space missions.
- AMA Journal of Ethics - “Prevention” and Human Gene Editing Governance - Analysis of different conceptions of prevention in governance.